Zhu Nanlin, Huang Suling, Zhang Qingli, Zhao Zhuohui, Qu Hui, Ning Mengmeng, Leng Ying, Liu Jia
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Metabolites. 2021 Jun 10;11(6):374. doi: 10.3390/metabo11060374.
The pathophysiology of nonalcoholic fatty liver disease (NAFLD) is a complex process involving metabolic and inflammatory changes in livers and other organs, but the pathogenesis is still not well clarified. Two mouse models were established to study metabolic alteration of nonalcoholic fatty liver and nonalcoholic steatohepatitis, respectively. The concentrations of metabolites in serum, liver and intestine content were measured by the AbsoluteIDQ p180 Kit (Biocrates Life Sciences, Innsbruck, Austria). Multivariate statistical methods, pathway analysis, enrichment analysis and correlation analysis were performed to analyze metabolomic data. The metabolic characteristics of liver, serum and intestine content could be distinctly distinguished from each group, indicating the occurrence of metabolic disturbance. Among them, metabolic alteration of liver and intestine content was more significant. Based on the metabolic data of liver, 19 differential metabolites were discovered between DIO and control, 12 between DIO-CCl and DIO, and 47 between DIO-CCl and normal. These metabolites were mainly associated with aminoacyl-tRNA biosynthesis, nitrogen metabolism, lipid metabolism, glyoxylate and dicarboxylate metabolism, and amino metabolism. Further study revealed that the intervention of obeticholic acid (OCA) could partly reverse the damage of CCl. The correlation analysis of metabolite levels and clinical parameters showed that phosphatidylcholines were negatively associated with serum alanine aminotransferase, aspartate aminotransferase, NAFLD activity score, and fibrosis score, while lysophosphatidylcholines, sphingomyelins, amino acids, and acylcarnitines shared the reverse pattern. Our study investigated metabolic alteration among control, NAFLD model, and OCA treatment groups, providing preclinical information to understand the mechanism of NAFLD and amelioration of OCA.
非酒精性脂肪性肝病(NAFLD)的病理生理学是一个复杂的过程,涉及肝脏和其他器官的代谢及炎症变化,但其发病机制仍未完全阐明。本研究建立了两种小鼠模型,分别用于研究非酒精性脂肪肝和非酒精性脂肪性肝炎的代谢改变。采用AbsoluteIDQ p180试剂盒(奥地利因斯布鲁克市的Biocrates Life Sciences公司)测定血清、肝脏和肠道内容物中的代谢物浓度。运用多变量统计方法、通路分析、富集分析和相关性分析对代谢组学数据进行分析。结果发现,每组肝脏、血清和肠道内容物的代谢特征存在明显差异,提示代谢紊乱的发生。其中,肝脏和肠道内容物的代谢改变更为显著。基于肝脏的代谢数据,在饮食诱导肥胖(DIO)组与对照组之间发现了19种差异代谢物,在DIO-四氯化碳(DIO-CCl)组与DIO组之间发现了12种,在DIO-CCl组与正常组之间发现了47种。这些代谢物主要与氨酰-tRNA生物合成、氮代谢、脂质代谢、乙醛酸和二羧酸代谢以及氨基酸代谢相关。进一步研究表明,奥贝胆酸(OCA)干预可部分逆转四氯化碳造成的损伤。代谢物水平与临床参数的相关性分析显示,磷脂酰胆碱与血清丙氨酸氨基转移酶、天冬氨酸氨基转移酶、NAFLD活动评分及纤维化评分呈负相关,而溶血磷脂酰胆碱、鞘磷脂、氨基酸和酰基肉碱则呈现相反的模式。本研究调查了对照组、NAFLD模型组和OCA治疗组之间的代谢改变,为理解NAFLD的发病机制及OCA的改善作用提供了临床前信息。